ipid changes in schizophrenia patients compared to healthy controls
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2021/08/035496
- Lead Sponsor
- Shivaprakash G
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Cases: Objective 1
1. All diagnosed schizophrenia cases who are antipsychotic drug-free defined as 1 month for oral drugs and 3 months for injectable depots at the time of recruitment.
2. Drug-naïve schizophrenia cases diagnosed as per DSM- 5 by the psychiatrist, presenting at psychiatry department will be included.
Control: The healthy control group, matched for age, gender [among the hospital staff and their family members and friends of same community with no personal and family history [I and II degree relatives] of psychotic illness.
Objective 2 &3 :
Inclusion
All drug-naïve and drug-free SCZ patients diagnosed as per DSM 5 who were started with antipsychotic drugs
Objective 1
•Metabolic syndrome and other medical disorders, acutely ill cases, cancer
•Patient on history of taking antipsychotics within last 1 month for oral drugs and 3 months for depot formulation, cholesterol lowering agents, substance abuse, immunomodulatory treatment
•Dietary supplementation with Polyunsaturated fatty acids or other lipids as therapy.
Objective 2 and 3:
•Metabolic syndrome and other medical disorders, acutely ill cases, cancer
•Patient on cholesterol lowering agents, substance abuse, immunomodulatory treatment
•Dietary supplementation with Polyunsaturated fatty acids or other lipids as therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood for Lipidomics of Extracellular Vesicles in both cases and control groups at V0 and V2; <br/ ><br>BPRS, Cognition assessments in cases at V2Timepoint: Baseline V0 and V2 at 8±2 weeks
- Secondary Outcome Measures
Name Time Method ilTimepoint: Nil